Nuevolution AB (publ) announced first animal preclinical data suggesting a potential positive synergistic anticancer effect of combining Nuevolution's BET-BD1 compound, NUE20798, with an antibody immunotherapy. Nuevolution has developed potent and selective compounds, with a benign safety profile targeting the first bromodomain of the BET family of proteins. Previous data from the program have identified specific genes responsible for human fibrosis to be potently suppressed by the company's BET-BD1 inhibitors thereby supporting a potential use for such inhibitors in treatment of human fibrotic diseases. Based on these preliminary data, Nuevolution have now initiated further cancer model studies using NUE20798 to investigate for dose-dependent activity and tumor fibrosis biomarker responses. If also positive, such further data may expand development options for the Nuevolution BET-BD1 program within cancer combination treatments, complementing the current route within fibrotic diseases and atopic dermatitis.